Full Alliance Group Inc. (FAGI)

[balamidas]

EBO2 is already out in the market being marketed as we speak and your mentioned company intends to submit an Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) and initiate clinical trials based on January PR.BioXyTran is planning a comprehensive study of the drugs applications in not only supplying oxygen in cases of hypoxia but also recovery of brain cells in the aftermath of a stroke.


so the patient will prefer a needle and recover and stay alive instead of waiting 10 years for them to get the BXT 25 to market through clinical trials and FDA approvals


10 years is the approximate time of clinical trials from IND till drug reaches the market

http://www.aviseanalytics.com/bxt-25-can-bioxytran-incs-novel-drug-revolutionize-oxygen-delivery/


Still a stock to watch in the near future

Thanks for bringing it to my attention